SSM Score for Liver Injury in Chronic Liver Disease
Part of Digestive system clinical trials.
This study looks at how well a simple score (called SSM) can predict recovery in people with chronic liver disease who suddenly get a liver injury with jaundice. It may help your doctors understand how serious your condition is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a chronic (long-term) liver condition of any cause (for example, cirrhosis or hepatitis).
- You have a sudden worsening of your liver, with jaundice and a bilirubin level of 3 mg/dL or higher.
- You have not had a liver transplant, TIPS procedure, or spleen surgery for your liver disease.
- You do not have severe lung disease, kidney failure on dialysis, or a recent heart attack.
- You are not being treated with immune-suppressing drugs for a reason other than your liver disease.
- You do not have liver cancer or any other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple, non-invasive ultrasound test of your spleen and routine blood tests to see if your liver can start working better after treatment. It is for people whose cirrhosis has recently caused complications but who are now doing well on treatment.
This study looks at people over 18 who have advanced, long-term liver scarring. It uses specialized measurements of liver stiffness and pressure to confirm eligibility and may help doctors better understand this condition.
This study looks at new, non-invasive methods to predict when chronic liver disease might get worse. It could help you and your doctor catch problems early without needing a biopsy or other invasive procedures.
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Hear when a new End Stage Liver DIsease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.